Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 4 Sept 2014 |
| Orion Group Interim Report January-June 2014 | 29 Jul 2014 |
| Orion Corporation's publication schedules for financial reporting in 2015 | 29 Jul 2014 |
| Publishing of Orion Corporation's Interim Report for January-June 2014 on 29 July 2014 | 16 Jul 2014 |
| 150,000 Orion A-shares converted into B-shares | 4 Jul 2014 |